Barclays’s DarioHealth DRIO Stock Holding History

Barclays’s Portfolio DRIO Stock Details DRIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-26	Closed	-$172	–	5475
2026 Q2	$172	Buy	+26	New	+$193	﹤0.01%	5132
2025 Q2	–	Sell	-2	Closed	-$21	–	5337
2025 Q1	$21	Buy	+2	New	+$28	﹤0.01%	5169
2022 Q2	–	Sell	-109	Closed	-$13K	–	5079
2022 Q1	$13K	Buy	+109	New	+$18K	﹤0.01%	4547

Other funds holding DRIO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

North Star Investment Management Chicago, Illinois $1.85B AUM 21.53% 1-Year Est. Return

Barclays's DRIO Position: Q3 2026 in Review

Barclays sold out of DarioHealth (DRIO) in Q3 2026, closing a stake of 26 shares — an estimated $172 sold.

Barclays first reported a position in DRIO in Q1 2022 and held it in 3 quarters. The position peaked at $13K in Q1 2022. 5 funds tracked by Wall St. Rank hold DRIO as of Q3 2026.

Barclays reported no remaining DarioHealth position as of Q3 2026 after selling out during the quarter.
Barclays sold 26 DarioHealth shares in Q3 2026, an estimated $172.
Barclays first reported a position in DarioHealth in Q1 2022 and held it in 3 quarters.
Barclays's DarioHealth position peaked at $13K in Q1 2022.
5 funds tracked by Wall St. Rank held DarioHealth as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.